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Abstract: Resveratrol, (3, 5, 4'-trihydroxystilbene) is a non-flavonoid polyphenol stilbene 
synthesized by plants when damaged by infectious diseases or ionizing radiation. Although 
present in more than seventy plant species, grapes and wine are the major dietary contributors 
of resveratrol, responsible for 98% of the daily intake. In 1992, Renaud and De Lorgeril first 
linked wine polyphenols, including resveratrol, to the potential health benefits ascribed to 
regular and moderate wine consumption (the so called “French Paradox”). Since then, 
resveratrol has received increasing scientific interest, leading to research on its biological 
actions, and to a large number of published papers, which have been collected and discussed 
in this review. The relatively low amounts of resveratrol measured in wine following 
moderate consumption, however, may be insufficient to mitigate biological damage, such as 
that due to oxidative stress. On this basis, the authors also highlight the importance of 
viticulture and the winemaking process to enhance resveratrol concentrations in wine in order 
to bolster potential health benefits. 
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Introduction 
It is well known that a healthy diet is one of the most potent tools to avoid any kind of 
malnutrition, as well as to reduce risk factors for chronic pathologies such as cancer, 
cardiovascular diseases, diabetes and dementia. A balanced diet must supply the suitable 
amount of energy and nutrients to maintain the desirable body weight and homeostasis. In this 
	
	
	
	
3	
regard, several national and international guidelines have been published to guide the choices 
of consumers and public organizations (EFSA; 2017; JECFA, 2003; USDA, 2015),  In the last 
few decades, besides the nutritional balance, a relatively new concept on the proper intake 
with the diet of functional compounds (for example antioxidants such as polyphenols) has 
been introduced; in fact, while not providing energy, they can contribute critically to the 
general health of consumers (Vanzour et al., 2010; Cvejic and Gojkovic-Bukarica, 2016). 
Aging and, consequently, chronic non-transmissible or lifestyle diseases such as 
cardiovascular diseases, diabetes, oncological and neurodegenerative diseases, start as 
functional problems many years before their clinical manifestations. Aging as a concept of 
use and wear, as well as an accumulation of damages in molecular structures over time have a 
common denominator, namely, oxidative stress. Oxidative stress is an increase in free radical 
production and/or a decrease in the production of antioxidant molecules (Sies, 1985; 
Hernández Saavedra and Mc Cord, 2007; Pisoschi and Pop, 2015). Cellular biology covers 
the energy demands of metabolism through organelles such as mitochondria. In order to 
accomplish this mitochondria, which can be considered as chemical machines, work at 
constant pressure and temperature to produce energy (adenosine triphosphate or ATP) 24 
hours a day, which is used in energy exchanges. As part of this energy production process, 
however, mitochondria also produce metabolic waste, that is, oxygen free radicals (OFR). 
One to three percent of the oxygen that cells breathe (which is equivalent to 4 to 12 liters of 
oxygen/day for humans) leaks from the respiratory mitochondrial chain, goes through their 
membrane and remains in the cell as OFR (Boveris et al., 1972), producing an accumulation 
of acid waste, molecular damages, diseases and aging (Boveris, 2005; Raha and Robinson, 
2000). Therefore, mitochondria, the main source of cellular energy, are also the source of 
95% of the body’s OFR (Stotland and Gottlieb, 2015). Correspondingly, evolving biology has 
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adapted by means of a system of “antioxidant defense” inside the intracellular compartment to 
protect itself from damages caused by its own functioning (Table 1). 
Unlike intracellular spaces, the antioxidant defenses of intravascular and intestinal lumen 
spaces depend almost exclusively on the food supply, which makes them vulnerable to 
oxidative stress if the supply is ‘unsuitable’. In other words, the lifestyle-related prevention is 
greatly significant to fight the redox imbalance. As Table 1 shows, the intracellular 
antioxidant defense system is dual and based on endogenous enzymatic system and a non-
enzymatic foodborne system. Eventually, the enzymatic system is defeated by the damage 
produced by OFR, causing an increase of oxidative stress (Sies, 1985; Hernández Saavedra 
and McCord, 2007; Pisoschi and Pop, 2015). It has been shown that after 20 years of age, 
intracellular antioxidant defenses as measured by glutathione concentration start decreasing at 
approximately 1.2% per year due to OFR damage (Samiec et al, 1998; Maher, 2005). 
Therefore, oxidative stress caused by OFR is the side-effect of energy production due to the 
comburent used, which is oxygen (Barja, 2014). As shown in Figure 1, during human life, 
three stages can be potentially identified in redox homeostasis: the first one is ‘full health’ 
period, up to 28 to 30 years old, when antioxidant defenses are balanced in number with pro-
oxidant molecules. The second stage is the ‘healthy’ period (apparent wellbeing), between 30 
and 60 years old, when there is a redox imbalance with oxidative stress produced by the 
deterioration associated with aging, being sedentary, overweight or obesity, an increased and 
unbalanced plasma cholesterol concentration, and physical or psychological stress. During 
this stage, the ‘healthy’ situation is relative due to redox imbalance and lifestyle-related 
prevention is greatly significant. After turning approximately 60 years old, a third stage 
begins called ‘illness’ period with possible clinical manifestations. 
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As shown in Figure 2, during this third stage (illness), total oxidative stress is the sum of what 
has been provided by cellular breathing (level 1), oxidative stress by physiological stimulation 
(e.g. postprandial) (level 2), metabolic waste and other disease risk factors such as high blood 
pressure, obesity, dyslipoproteinemia, chronic inflammatory processes and diabetes mellitus 
(levels 3 to 6). 
The measurement of the body’s antioxidant defenses could become usual practice in the 
future to evaluate risk factors for chronic diseases, in addition to blood pressure and body 
weight. For example, a quantification of skin carotenoids by resonance Raman Spectroscopy 
has been suggested by Mayne et al. (2013). A decrease in antioxidant defenses may act as an 
alert to change dietary practices or to use antioxidant dietary supplements to reduce the risk of 
cardiovascular, metabolic or neurodegenerative diseases, as well as that of cancer. Non-
invasive Raman Spectroscopy is a technique that can be used to measure antioxidant defenses 
(Ermakov and Gellerman, 2010).  
As cells do not have antioxidant reserves, if intestinal digestion causes oxidative stress and 
there is not an appropriate dietary antioxidant balance, the cellular structures of the internal 
milieu may be damaged (Rahal et al., 2014).  
Potential benefits of drinking red wine with meals have been partly ascribed to wine’s 
relatively large content of polyphenols such as resveratrol (Das and Das, 2010). Polyphenols 
have been shown to reduce the damaging effects of OFR during food digestion and absorption 
(Karatzi et al., 2008). Nourishment may become a risky habit, therefore, if there is not an 
appropriate redox balance in nutrients. 
 
Resveratrol  
Resveratrol (3, 5, 4′-trihydroxystilbene) is a phytoalexin, non-flavonoid polyphenol present in 
more than 70 plant species. Only a few of these plants are edible and among the latter, the 
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most important are: Vitis vinifera (grape), Arachis hypogaea (peanut), Theobroma cacao 
(cacao), plants producing berries (Vaccinium myrtillus, Ribes nigrum, Rubus idaeus, etc) and 
their relative by-product (such as red wine, chocolate, juices, etc.). It has been shown that 
resveratrol has in vitro anti-inflammatory effects and, accordingly, has been used as dietary 
supplement in animal models to increase longevity and improve health in mice fed with high 
caloric content (Baur et al., 2006; Birrell et al., 2005; Rahman, 2006). Dietary studies in 
animal models have shown that resveratrol and other chemically related compounds activate 
SIRT1 (Cantó and Auwerks, 2012; Timmer et al., 2012), and imitate the effects of caloric 
restriction (Lee and Min, 2013; Wu and Hsieh, 2011); sirtuins are a family of deacetylase 
enzymes that, when activated, silence DNA information. The interest in resveratrol in 
nutrition and medicine started in 1992, when resveratrol was identified as a possible 
explanation for cardiovascular protective effects associated with the intake of red wine in 
"The French Paradox" (Siemann and Creasy, 1992; Renaud and De Lorgeril, 1992). One 
potential cardioprotective mechanism of action is the inhibition of low density lipoprotein 
(LDL) oxidation (Frankel et al., 1993; Frankel et al., 1995). Potential cancer preventive 
effects have also been proposed for resveratrol (Jang et al., 1997; Carter et al., 2014; Xue et 
al., 2014). Such data increased the interest of scientists, the general public and the 
pharmaceutical and dietary supplement industries, where a  bibliographic search in Pubmed 
using ‘resveratrol’ as the keyword currently delivers more than 9,000 publications.  
Numerous research efforts explored resveratrol’s biological mechanisms of actions. There are, 
however, certain limitations that create doubts when extrapolating the results of basic in vitro 
and ex vivo research to human health. For example, basic research often involves dietary 
interventions with relatively high doses of resveratrol compared to those naturally found in 
wine (Linn et al., 2016; Wong et al., 2016).  
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It is well known that the food matrix is important in modifying intestinal absorption, 
bioavailability, pharmacokinetics of molecules and, as a consequence, animal and human 
health outcomes (Stockley et al., 2012). In general, lipophilic resveratrol has been shown to 
be highly absorbed after oral ingestion and extensively and rapidly metabolised through 
glucuronidation and sulfatation reactions in the liver, and also through hydrogenation of the 
aliphatic double bond in the intestine (Soleas et al., 2001; Meng et al., 2004; Goldberg et al., 
2003; Walle et al., 2004).  Human studies by Walle et al. (2004) on the oral absorption of 14C-
resveratrol showed that the elimination half-life of total resveratrol metabolites is about 6 to 
15 hours after oral doses. Resveratrol metabolites can be detected in the urine of humans 
consuming one glass of wine per week, if the last drink was consumed three days previously, 
or in those consuming three glasses of wine per week, if the last drink was consumed five 
days previously (Zamora-Ros et al., 2006; Zamora-Ros et al., 2009). 
Despite its low bioavailability, resveratrol may show efficacy in vivo through its metabolites 
or derivatives (Stockley et al., 2012). In plasma, unmetabolised resveratrol binds to both 
albumin and lipoproteins such as LDL (Gambini et al., 2015). These complexes, in turn, can 
be dissociated at cellular membranes, which have receptors for albumin and LDL, leaving the 
resveratrol free and allowing it to enter cells.  Accordingly, resveratrol may interact with 
extracellular and intracellular molecules, and its mechanism of action at the cellular level may 
be triggered by either activating signaling pathways, when binding to cell membrane 
receptors, activating intracellular mechanisms, or even developing its effects inside the 
nucleus. In addition, its efficacy may also be explained by the conversion of both sulfates and 
glucuronides back to resveratrol in target organs, such as the liver and intestine (Vitrac et al., 
2003; Wenzel and Somoza, 2005). In addition, in vivo effects may be attributable to its 
bioactive metabolites, which are measurable in plasma and urine post oral ingestion 
(Vitaglione et al., 2005, Boocock et al., 2007). 
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Resveratrol daily intake 
Different studies have calculated the daily dietary intake of resveratrol or total stilbenes, but 
results are not always in agreement (Rabassa et al., 2015; Siemann and Creasy, 1992; 
Zamora-Ros et al., 2006; Zamora-Ros et al., 2008; Zamora-Ros et al., 2009; Zamora-Ros et 
al., 2012). According to a relatively recent study (Rabassa et al., 2015), the daily intake of 
total resveratrol (total stilbenes) is in the order of few mg/day, where red wine is the richest 
source (approximately 90%). 
 
 
Resveratrol and human health: criteria for literature search 
In this review, papers reporting human studies on resveratrol intake and benefits are collected 
and discussed, according to the body of evidence. Two of the most important scientific 
databases of references and abstracts on life sciences and biomedical topics, 
PubMed/MEDLINE and Embase, were systematically searched to create the present work. 
The following search strategy and selection criteria were used: data were collected from 
database inception to April 2017, with the terms “clinical trial”, “benefits”, “health”, in 
combination with “resveratrol”. Additional search criteria were: human study; oral exposure; 
and controlled trial. 
 
Results 
Since 2009, there has been a proliferation of resveratrol-related dietary interventions in 
patients treated for different pathologies and in healthy volunteers with risk factors. Searches 
from 1970 to 2008 produced mainly studies performed in vitro or in laboratory animals. The 
papers selected according to the inclusion criteria are listed in Table 2. 
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The Spanish PREDIMED study was one of the first studies to assess the association between 
moderate wine consumption, resveratrol intake and cardiovascular (CVD) risk factors in 1000 
participants including high cardiovascular risk patients (Zamora-Ros et al., 2012). Measuring 
the total resveratrol metabolites (TRMs) in urine as biomarkers of exposure, the authors 
showed that moderate wine consumption as well as resveratrol intake can positively modulate 
some recognized CVD risk factors, such as blood lipid profiles, fasting blood glucose 
(significant changes only with resveratrol) and heart rate. Data collected indicated that 
resveratrol intake (as such or with wine) might help to decrease CVD risk factors. 
A second study by Semba et al. (2014), assessed whether dietary resveratrol intake,  but not 
specifically wine consumption, modulated events associated with inflammation, CVD, cancer 
and mortality. It was a prospective cohort study involving 783 community-dwelling men and 
women aged 65 years or older in two villages of the Chianti area, from 1998 to 2009. Urines 
were analysed to measure the level of resveratrol metabolites (URM), and population was 
classified in quartiles: <1554 (n= 195), 1554-4996 (n= 196), 4996-15010 (n= 196), and 
>15010 (n= 196) nmol URM/ g creatinine. During the nine years of follow-up, 268 (34.2%) 
of the perticipants died. The relationship between URM and all-cause of mortality was 
statistically evaluated and no significant correlation was found, when the model was adjusted 
for age, sex, BMI, serum level of lipids, and chronic diseases. In details,  no differences was 
observed between quartiles for hearth failure, periferal artery disease, stroke, diabetes melitus, 
cancer, chronic kidney disease, and overall mortality. 
To better evaluate the result of the study, the authors calculated  the average daily dietary 
consumption of resveratrol in this population during the follow up. The mean log dietary 
intake of resveratrol (mg) were: -2.71 (- 2.87 to -2.55) at 3 months; -2.82 (-2.99 to -2.64) at 6 
months; and – 2.66 (-2.81 to -2.50) at 9 months. This amount appeared insufficient to have a 
significant influence on health status and mortality risk of participants. Moreover, the lack of 
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the expected association may reflect variability in resveratrol intake, inter-individual 
variation, and variability of host-gut microbiota (Blaut and Clavell, 2007; Nicholson et al., 
2012) indicating that a much larger sample size is required to reach final conclusions. 
 These contradictory studies, therefore, suggest that the next research step is the identification 
of an effective ‘dose’ of resveratrol necessary to benefit human health. Summarizing the data 
collected in this paper (Table 3 and 4), the most significant beneficial health effects are 
associated with the cardiovascular system. The lowest active amount of resveratrol identified 
was 30 mg/day to improve endothelial function in healthy individuals (Wong et al., 2011). A 
wide range of resveratrol ‘doses’ has been associated with the improvement of other 
physiological/pathological functions and parameters or reduction of risk factors. 
 
The effects of viticulture and winemaking practices on resveratrol concentrations in 
wine 
Resveratrol exists in both cis and trans forms in wine, but trans-resveratrol predominates in 
grapes and may be methylated and polymerized to produce piceid, pterostilbene and the 
viniferins, respectively, and glycosylated during fermentation (Jeandet et al., 1995a; 
Langcake, 1981; Pezet and Cuenat, 1996). The average concentration of total resveratrol in 
red wine is 7 mg/L and is 2 mg/L in rosé and 0.5 mg/L in white wine, but ranges widely 
according to grape variety, geographical indication and vintage (Waterhouse, 2002). In 
contrast to other grape-derived phenolic compounds produced in the skins and seeds of grapes 
in response to increased sunlight and temperature (Spayd et al., 2002), resveratrol acts like a 
phytoalexin and is produced by the skin cells of grapes and by the leaves in response to 
Botrytis cinerea, Plasmopara viticola, Rhizopus stolonifer, Uncinula necator and other fungal 
infections on grapevines, as well as in response to UV light, radiation and related external 
stimuli (Ector et al., 1996; Adrian, 2000; Gershman et al., 1954). Resveratrol is also 
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synthesized by unstressed vines but to a significantly lesser degree (Pezet et al., 1996). 
Disease-resistant plant genotypes quickly produce and accumulate resveratrol while in 
susceptible species, such as Vitis vinifera, production occurs more slowly. The cultivar Pinot 
Noir appears quite susceptible to fungal infection and hence generally produces and 
accumulates a higher concentration of resveratrol than other varieties, irrespective of 
viticultural origin (Siemann and Creasy, 1992; Goldberg et al., 1995, Jeandet et al., 1995b). 
Accordingly, a high concentration of resveratrol has been consistently measured in wines 
from cooler climate regions reflecting a cool damp climate and increased fungal pressure, 
such as Ontario in Canada, and Bordeaux and the Rhone Valley in France, although some 
sub-regional differences were also observed (Goldberg et al., 1995; Soleas et al., 1997). 
Conversely, a significantly lower concentration of resveratrol has been measured in wines 
from relatively warm and dry climates. In grape berries infected with powdery mildew, 
however, the concentration of resveratrol appears to be correlated with the fungal pressure 
(Romero-Perez et al., 2001). Studies suggest also that although the synthesis of resveratrol is 
induced and increases as climatic conditions lead to Botrytis cinerea infection, excessively 
heavy infection actually degrades the induced resveratrol by activating an exocellular laccase-
like stilbene oxidase, so that a relatively low concentration of resveratrol is measured in wines 
from a vintage where there is heavy Botrytis cinerea pressure (Pezet et al., 1991; Jeandet et 
al., 1995b). 
In nutraceutical research, ultrasonication techniques have been applied to enhance the 
accumulation of secondary metabolites in plants. Ultrasonication techniques have recently 
been applied to increase the accumulation of resveratrol in grape skins and leaves (Hasan and 
Baek, 2013). The accumulation of resveratrol increased in grape skin by 7.7-fold after 
ultrasonication treatment for 5 minutes, followed by incubation for a further 6 hours. The 
increase of resveratrol in leaves, however, was less than that in grape skin. The amount of 
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increased resveratrol in grape leaves after 15 minutes of ultrasonication, followed by a 3-hour 
incubation, was 1.8-fold higher than that observed in non-treated controls. The accumulation 
of resveratrol in both grape skin and leaves was dependent on the ultrasonication time and the 
incubation period. Resveratrol-enriched grape juice has also been observed using 
ultrasonication treatment reported in previous work (Hasan et al., 2014). In all the grape 
varieties used, significantly higher amounts of resveratrol were observed in grape juice 
manufactured from fruit treated with ultrasonication of the grape skins of cultivars Campbell 
Early, MBA, and Kyoho:; the content of resveratrol in juices increased by 1.53, 1.15, and 1.24 
times, respectively. 
The concentration of phenolic compounds in wine is also influenced by winemaking variable 
(Revilla et al., 2001). The extraction of total phenolic compounds during winemaking from 
the skins, seeds and flesh of grape berries into must, however, rarely exceeds 50% of the total 
amount present originally in the grape (Somers and Vérette, 1988). In general, white wine is 
made by fermenting juice from which grape skins and seeds have been removed, and red wine 
is made by fermenting juice in the presence of grape skins and seeds. Fermentation with solid 
grape material allows the aqueous and alcoholic extraction of phenolic compounds from the 
skins and seeds. The concentration of total phenolic compounds in wine consequently 
increases during fermentation with skins and seeds, but may subsequently decrease as some of 
the phenolic compounds combine with proteins and yeast hulls and precipitate. The 
concentration of total phenolic compounds continues to decrease with fining and filtration, 
and during maturation. 
As phenolic compounds are primarily located in the skins and seeds of grape berries, it is 
implicit that winemaking practices, which influence the extraction of these compounds from 
the skins and seeds into the wine, would influence their concentration in the final wine. 
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The influence of winemaking techniques in conjunction with grape variety on the resveratrol 
concentration in wines has also been studied for the cultivars Merlot, Cabernet Sauvignon and 
Prokupac as well as for Pinot Noir (Atanacković et al., 2012). Applied winemaking 
technologies included thermovinification and the separation of must from pomace. The total 
resveratrol concentration in analysed wine samples ranged from 0.35 to 4.85 mg/L. Merlot 
wines had the highest average resveratrol concentration, while the lowest was found for the 
native cultivar Prokupac.  
Although resveratrol concentrations in the red wines depended on the grape variety, 
correlation between the applied winemaking technology and the concentration of resveratrol 
in wines was not observed.  Data suggests, however, that the most important factor in 
winemaking is the maceration time, since the highest concentrations of resveratrol and piceid, 
and the highest antioxidant activity were found following six and ten days of maceration for 
Vranec and Merlot wines (Kostadinović et al., 2012). In addition, the techniques of skin 
extraction and enzymatic hydrolysis of glucoside forms play an important role in resultant 
resveratrol concentration of wine, because stilbenes compounds are mainly found in skin cells 
of the berry (Bavaresco et al., 2012).  
To enhance resveratrol concentrations in wine pre and post fermentation, must could be 
enriched with resveratrol-rich grape skins and press wine could be added to free run juice.   
Alternatively, grape-derived resveratrol could simply be added during winemaking; however 
this practice is not allowed in all countries.  Sulfur dioxide is added during winemaking to 
inhibit the growth of unwanted yeasts and bacteria, and to protect wine from oxidation. Sulfur 
dioxide is, however, associated with allergies and sensitivities in susceptible individuals, 
which is reflected in mandated warning labelling for added amounts greater than 10 mg/L 
(Stockley and Johnson, 2015). Consequently, alternatives to sulfur doxide are being sought. A 
pilot study assessed the replacement of sulfur dioxide with the antioxidant resveratrol during 
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winemaking (Pastor et al., 2015). Two different amounts of resveratrol (150 mg/L and 300 
mg/L), along with reduced or no sulfur dioxide added during winemaking (Pastor et al., 
2015), had similar effects on the organoleptic or sensory properties of the resultant wine. The 
benefical effects of adding resveratrol to reduce or replace sulfur dioxide is two-fold for 
consumers ─ a reduced risk of an adverse reaction with a potentially reduced risk of 
mortality. 
Conclusions 
The oxidative stress is an imbalance between antioxidant molecules production and the 
oxygen reactive species, which are a natural consequence of cellular breathing that produces 
energy and is performed in mitochondria. This homeostasis is a delicate balance in molecular 
biology aimed to maintain the suitable Redox potential. If the redox potential increases, it 
means that we are facing an increased production of oxygen free radicals, which is one of the 
first risk factors of non-transmissible chronic diseases of aging and its consequences like 
cardiovascular, metabolic and neurodegenerative diseases and cancer. Given that the world’s 
population is growing at an unprecedented rate, where percentage of people worldwide aged 
65 and over is projected to double to approximately 17 percent of the world's population by 
2050 (He et al.. 2016), research into simple dietary interventions to reduce the risk these 
chronic diseases have become increasingly important.  Resveratrol has been consistently 
shown to be a biologically active compound since 1992, having potential effects on human 
health and diseases. Wine is the main sources of dietary resveratrol although average intake is 
in the order of few mg/day and it is not enough to support healthy biological actions. 
Therefore, we need to thoroughly investigate resveratrol’s effects in humans and explores 
means to increases its concentration to be biologically relevant in foods (mainly fruits and 
derivatives) and beverages (such as juices and wine). 
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ABBREVIATIONS 
 
ALT=Alanine aminotransferase 
AMPK=AMP-activated protein kinase 
APC= Antigen presenting cells 
ApoB100=Apolipoprotein B100 
ApoB48=Apolipoprotein B48 
AUC=Area Under the Curve 
BMI=Body Mass Index 
BNP=Brain natriuretic Peptide 
CAD=Coronary Artery Disease 
CCL3=Chemokine (C-C motif) ligand 3 
CCND2= G1/S specific cyclin-D2 gene 
CF=calcium fructoborate 
CRP=C-reactive protein 
CVD=Cardiovascular disease 
CYP1A2=Cytochrome P450 1A2 
CYP2D6 =Cytochrome P450 2D6 
CYP3A4=Cytochrome P450 3A4 
FMD=Flow Mediated Dilatation 
GE=Grape extract 
GE-RES=Grape-extract resveratrol 
GLP1=Glucagon-like peptide 1 
HbA1c= Glicated hemoglobin 
HDL=High Density Lipoprotein 
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HDLcol=cholesterol-HDL 
Hs-CRP=high sensitive C reactive protein 
IGF-1=Insulin like grow factor 1 
IGFBP3= Insulin like grow factor binding protein 3 
IL-10=Interleukin-10 
IL-6=Interleukin-6 
LDL=Low Density Lipoproteins 
LDLcol=cholesterol-LDL 
NAMPT=Nicotinamide phosphoribosyltransferase  
NF-kB=Nuclear Factor –kB 
NO=Nitric Oxide 
OFR= Oxygen Free Radicals 
Ox-LDL=Oxidized-LDL 
PAI-1=Plasminogen activator inhibitor-1 
PBMCs=Peripheral Blood Mononuclear Cells 
PGC1=Peroxisome proliferator activated receptor gamma coactivator 1 
PPARGC1A=Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 alpha 
RASSSF-1=Ras association domain-containing protein 1-alpha gene 
RES=Resveratrol 
SIRT1=Sirtuin 1 
T2DM=Type 2 Diabetes mellitus 
TNF-alpha=Tumor necrosis alfa 
UC=Ulcerative colitis 
UF=Ultrafiltrate 
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Table 1: Antioxidant defense systems in intracellular, intravascular and intestinal lumen spaces 
 
Source of antioxidant 
defense 
Specific molecule Intracellular space Intravascular space Intestinal lumen 
Endogenous enzymes Catalase X   
Glutathione peroxidase X  X 
Superoxide dismutase X   
    
Endogenous antioxidant Glutathione X   
    
Active molecules from 
food 
Carotenes X X X 
Vitamin C X X X 
Vitamin E X X X 
Polyphenols X X X 
 
        Modified from Boveris, 2004  
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Table 2. Overview of selected studies regarding resveratrol-related dietary interventions from 1970 to 2016 
 
 Cohort,  
sample size (n)  
Trial type Resveratrol 
dosage 
Duration Target Main outcome Reference 
1 Patients with colon cancer (n=8). 
Four parallel arms, 
randomized trial.  
 
Uncontrolled and 
open trial. 
Daily intake of: 
80 g grape powder (GP) with 
0.07 mg RES, n=3; or 120 g GP 
with 0.11 mg RES, n=2; or 3.9 
mg RES + 120 mg quercetin, 
n=2; or 15.5 mg RES + 480 mg 
quercetin, n=1. 
19 days 
Changes in Wnt 
singnalling pathway in 
normal and cancer colon 
tissues after surgery. 
Inhibition of some genes 
from Wnt signalling 
pathway only in normal 
tissue. 
Nguyen et al., 
2009 
2 
Patients with 
colorectal 
cancer (n=20). 
 
Two parallel arms, 
non-randomized, 
blind, placebo 
uncontrolled. 
RES daily dose:  0.5 g, n=10; or 
1 g, n=10.  
 
RES in capsules. 
8 days 
Detection of RES and 
metabolites in colorectal 
tissue, and effect on 
proliferation marker Ki-
67. 
Ki-67 antigen level was 
reduced by 5% and 7% in 
cancer and normal tissue, 
respectively. 
Patel et al., 
2010 
3 
Patients with 
colorectal cancer and 
hepatic metastasis 
(n=6). 
 
Patients with 
colorectal cancer and 
hepatic metastasis 
(n=6). 
 
Two parallel arms, 
randomized, placebo. 
 
Preoperative daily intake  of a 
sachet containing 5 g of RES or 
placebo. 
From 10 
to 21 
days 
Pharmacokinetics, tissue 
disposition and effect on 
apoptosis marker 
(cleaved caspase-3). 
Detection of RES in 
hepatic tissue and 
increased (39%) content 
of cleaved caspase-3 in 
this tissue. 
Howells et al., 
2011 
4 
Twenty over weight 
or obese male 
subjects (age: 36.6-
61 yrs) with non-
alcoholic fatty liver 
disease. 
Open study, placebo-
controlled. 
 
Placebo or 3000 mg RES daily. 
Daily dose: 3 cps (500 mg) 
before breakfast and before 
bedtime (total 6 cps). They were 
instructed to maintain their 
lifestyle habits. 
8 weeks 
To determine if RES 
improves the parameters 
of non-alcoholic fatty 
liver disease. 
RES was well tolerated, 
although there were no 
significant results in 
insulin function, steatosis, 
or abdominal fat 
distribution. There were 
no changes in plasma 
markers of inflammation. 
Chachay et 
al., 2014 
5 
60 subjects with non 
alcoholic fatty liver 
disease. 
Double-blind, 
randomized, placebo-
controlled trial. 
Subjects were given placebo or 
2 cps containing 150 mg RES, 
twice daily. 
3 months 
To evaluate  the effect 
of RES on insulin 
resistance, glucose,  
epatic enzymes and lipid 
metabolism in 
nonalcoholic fatty liver 
disease. 
RES significantly 
decreased aspartate 
aminotransferase, glucose 
and LDL cholesterol 
Chen et al., 
2015 
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6 
49 patients (15 
females) with a 
history of non 
alcoholic fatty liver 
disease. Mean age of 
45.16. 
Randomized, double-
blinded, placebo-
controlled. 
Placebo or 500 mg/day of RES.  12 weeks 
To determine the effect 
of RES supplementation 
on liver enzymes and 
inflammatory markers in 
patients with 
nonalcoholic fatty liver 
disease. 
Significant decreases in 
both groups in circulating 
and liver inflammatory 
markers, and ALT levels 
in response to RES. 
Faghihzadeh 
et al., 2014 
7 
Patients on statin 
treatment and at high 
risk of CVD (n=75). 
Three parallel arms, 
randomized, triple 
blind, placebo 
controlled trial. 
Follow-up: daily ingestion of 
350 mg of 1) placebo (n=25), or  
2)  grape extract (GE) (n=25), 
or 3)  GE + 8 mg RES, (n=25).  
Product in capsules. 
6 months 
Effects on atherogenic 
markers, i.e. serum lipid 
profile, Apo B and 
LDLox. 
GE-RES decreased LDL-
cholesterol (4.5%);  Apo 
B (9.8%) and LDLox 
(20%), while GE 
determined only a 
significant decrease of 
LDL-cholesterol (2.9%). 
No drug interaction was 
detected. 
Tomé-
Carneiro et 
al., 2012a 
8 
Post-infarction 
patients  
(n=40) 
Randomized, 2 
parallel arms, double-
blind, placebo 
controlled trial.. 
Follow up: daily ingestion of 10 
mg RES (n=20) versus placebo 
(n=20).. RES in capsules. 
3 months Measure of biomarkers for cardioprotection. 
RES decreased LDLcol 
(8%); improved 
endothelial function 
(50%), and left 
ventricular diastolic 
function (2%), No effect 
on inflammatory 
parameters  
(CRP and TNFa). 
Magyar et al., 
2012 
9 
Patients on statin 
treatment and at high 
risk of CVD (n=75). 
(Same cohort as in 
Tomé-Carneiro et al. 
2012a). 
Three parallel arms, 
randomized, triple 
blind, dose-response, 
placebo-controlled 
trial. 
Follow-up: daily ingestion for 6 
months of 350 mg of 1) placebo 
(n=25), or  2)  grape extract 
(GE) (n=25), or 3)  GE + 8 mg 
RES, (n=25).  
Further treatment for 6 months 
with a double dose. Products in 
capsules. 
12 
months 
Effect on inflammatory 
and fibrinolytic status of 
patients. 
GE-RES decreased hs 
CRP (26%), TNF a (-
19.8%), PAI-1 (-16.8%) 
and IL-6/IL-10 ratio (-
24%), and increased IL-
10 (19.8%). No drug 
interaction was 
found. 
Tomé-
Carneiro et 
al., 2012b. 
10 
Patients with stable 
angina pectoris 
(n=116). 
Randomized, double-
blinded, active-
controlled. 
Follow up: oral supplementation 
with calcium fructoborate (CF) 
(112 mg/day), or RES 
(20 mg/day), or their 
combination 
30 and 
60 days 
Effect on inflammation 
biomarkers (hs CRP), 
left ventricular function 
markers (N-terminal 
prohormone of brain 
natriuretic peptide - 
Significant hs CRP 
decrease in all groups: 
39.7% in the CF group; 
30.3% in RES plus CF 
group. The N- terminal 
prohormone of BNP was 
Militaru et al., 
2013. 
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BNP), and lipid markers 
(total cholesterol, LDL-
c, HDL-c, and 
triacylglycerols). 
significantly lowered by 
RES (59.7% at 60 d) and 
by CF (52.6% at 60 
d). However, their 
combination was the 
most effective and 
induced a decrease of 
65.5%.  
Lipid markers showed no 
significant changes from 
baseline in all groups. 
11 
Patients with stable 
CAD (n=75). 
 
Three parallel arms, 
randomized, triple-
blind, dose response, 
placebo-controlled 
trial. 
Follow-up: daily ingestion of 
350 mg placebo (n=25), grape 
extract without (GE) (n=25); or 
with  8 mg RES (GE-RES), 
n=25) for 6 months, and the 
double dose for the following 6 
months. 
12 
months 
Effect on inflammatory 
and fibrinolytic status 
of patients. 
Significant increase in 
adiponectin levels (10%) 
in GE-RES group in 
addition to a decrease in 
PAI-1 levels. Non-HDL 
colesterol decreased 
significantly in both GE 
and GE-RES groups. 
Downregulation of 
pro-inflammatory genes 
expression in 
PBMCs isolated from 
GE-RES group patients. 
Tomé-
Carneiro et 
al., 2013a. 
12 
35 adult hypertensive 
men with a mean age 
of 60±11 years 
previously diagnosed 
with Type 2 diabetes 
(T2DM). 
Three parallel arms, 
randomized, triple-
blind, dose response, 
placebo-controlled 
trial. 
Daily intake of grape extract vs. 
RES-supplemented grape 
extract (8.1 ± 0.5 mg RES per 
capsule) for 6 months and 
double dose for the next 6 
months. 
12 
months 
To investigate the 
molecular changes in 
peripheral mononuclear 
cells in hypertensive 
patients with T2DM. 
Some cytokines were 
down-regulated, such as 
CCL3 and TNF-alfa;. 
RES modulated the 
expression of micro 
RNAs involved in the 
inflammatory response, 
including miR663 and 
miR-30c2. 
Tomé-
Carneiro et 
al., 2013b. 
13 
19 men with a 
diagnosis of 
schizofrenia, (18 -65 
yrs old), overweight 
or obese and/or  with 
metabolic disorders. 
Randomized, double-
blind, controlled trial 
The participants received a diet 
prescription one month before 
starting the study, then they 
received placebo or RES (200 
mg/day) per 4 weeks 
2 months 
 
To determine the 
efficacy of RES on 
serum glucose and CVD  
risk factors 
No change in body 
weight, waist 
circumference, serum 
glucose and cholesterol in 
the RES group. 
Changes in the lipid 
Zortea et al., 
2016. 
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profile. In the placebo 
group, there was a 
significant increase in 
total cholesterol, LDL-
cholesterol and in 
triglycerides, as well as a 
reduction in HDL-
cholesterol. 
14 
Patients with 
metabolic syndrome 
(n=34). 
Randomized, cross-
over, open trial; 
No control with 
placebo. 
Group A (n=17): Treatment 
with 100 mg RES in capsules 
for 3 months followed by 3 
months with placebo The 
inverse pattern in group B, 
n=17. 
6 months 
Evaluation of several 
parameters in patients 
with metabolic 
syndrome. 
In both groups, Flow-
Mediated-Dilatation 
(FMD) improved  
from 4% to 10% and 
returned to baseline 
values after 
discontinuation of 
RES treatment. No effect 
was observed on other 
inflammatory and 
atherogenic biomarkers. 
Fujitaka et al., 
2011. 
15 
24 patients 
previously diagnosed 
with metabolic 
syndrome (30 -50 
yrs; sex not 
indicated). 
Randomized, double-
blinded, placebo-
controlled. 
Placebo or 500 mg RES 3 times 
a day, before meals. 90 days 
To investigate the effect 
of RES on insulin 
release and efficacy in 
patients with metabolic 
syndrome. 
In the RES group, there 
were significant 
reductions in total weight, 
BMI, fat mass, and 
weight circumference. 
There were also 
significant differences in 
insulin sensitivity. 
Mendez del 
Villar et al., 
2014. 
16 
Type 2 male diabetic 
patients 
(n=19). 
Two parallel arms, 
randomized, double 
blind, placebo 
controlled trial. 
Daily ingestion of 10 mg RES, 
n=10 or placebo, n=9. RES in 
capsules.  
4 weeks Effect on insulin resistance 
Decrease of insulin 
resistance possibly due to 
a reduction of oxidative 
stress, as shown by  
measuring urine and 
platelet biomarkers 
Brasnyó et al., 
2011. 
17 Type 2 diabetics (n=62). 
Randomized trial, 
placebo- uncontrolled, 
open, 2 parallel arms. 
Daily ingestion of 
hypoglycemic drugs + 250 mg 
RES (n=28) or only 
hypoglycemic 
drugs in control group (n=29). 
Products in capsules. 
3 months 
Effects on glycemic 
control and associated 
risk markers. 
RES significantly  
improved concentration 
of: fasting glycemia (-
14.4%); systolic (-11.8%), 
and diastolic (-2,1%) 
blood 
Bhatt et al., 
2012. 
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pressures, HbA1c (-
0.3%), total colesterol (-
14.3%), and LDL-Col (-
12.5%); urea-nitrogen (-
3.23%9 
 
18 
 
Overweight/obese 
and moderately 
insulin resistant older 
adults (n=10). 
 
Randomized, placebo-
uncontrolled, open-
label trial 
 
RES capsules in one of the three 
doses: 1, 1.5, and 2 g/day 
 
4 weeks 
 
Glucose metabolism 
and vascular function. 
 
Improved insulin 
sensitivity and postmeal 
plasma glycemia. No 
change in fasting 
glycemia. No dose-
responce. 
 
Crandall et al., 
2012. 
19 
45 patients with diet-
controlled type-2 
diabetes. 
Double-blind, 
randomized, crossover 
design 
Patients received RES  (500 mg 
twice daily) or placebo over two 
5 wks intervention periods with 
a 5 wks washout, and then 
cross-over 
15 weeks 
To evaluate the effects 
of 5 week of RES 
treatment on GLP-1 
(glucagon-like peptide 
1) secretion, gastric 
emptying, and glycemic 
control in type-2 
diabetes. 
No significant change in 
both groups for any 
parameter measured. 
 
Thazhath et 
al., 2016. 
20 
10 males with Type 
2 diabetes mellitus 
(40-69 yrs old). 
Randomized, double-
blind, placebo 
controlled trial. 
Subjects were given a starting 
dose of 500 mg daily of either 
RES or placebo associated with 
a RES-free diet  
The dose was increased by 500 
mg/day every 3 days to a 
maximum dose of 3 g/day. 
Doses were divided in three 
administrations. 
15 days 
To assess  the effect of 
RES on skeletal muscle 
SIRT1 expression and 
energy expenditure. 
In patients with T2DM, 
the treatment with RES 
regulates energy 
expenditure through 
increased levels of 
skeletal muscle SIRT16 
and AMPK expression. 
These findings indicate 
that RES may have 
beneficial exercise-
mimetic effects in patients 
with T2DM 
Goh et al., 
2014. 
21 
Patients with 
Alzheimer Diseases 
(n=119). 
Two parallel arms, 
randomized, placebo 
controlled trial. 
Participants received placebo or 
resveratrol 500 mg orally once 
daily (with dose escalation by 
500-mg increments every 13 
weeks, ending with 1,000 mg 
twice daily). 
39 weeks 
Penetration of 
resveratrol and its major 
metabolites into the 
blood–brain barrier to 
have CNS effects. 
RES penetrates into 
cerebral spinal fluid and 
positively modulates 
biomarkers of Alzheimer 
disease. Further in-depth 
studies are suggested. 
Turner et al., 
2015. 
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22 80 post-menopausal women  (45–85 yrs). 
Randomized, double-
blind, placebo-
controlled trial.  
Two capsules of RES (75 
mg/day).  14 weeks 
To determine the effects 
of RES on cognition, 
cerebrovascular 
responsiveness to 
cognitive tasks and 
overall well-being 
According to the results 
of tests, RES, as other 
vasoactive nutrients, 
could enhance mood and 
cognition and reduce the 
risk of developing 
dementia in post-
menopausal women and 
other at-risk populations. 
Evans et al., 
2016. 
23 
72 patients with 
peritoneal dialysis 
(PD); 8 drop out. 
Double-blind, 
placebo-controlled, 
and randomized trial. 
Patients received placebo 
(n=24) or trans-RES 150 
mg/day  (n=22) or 450 mg/day 
(n=18),  
12-weeks 
To evaluate effects on 
angiogenesis-related 
markers. 
Over the 12-week period, 
patients in the high-dose 
group showed a 
significant  
improvement in mean net 
Ultrafiltration (UF) 
volume and UF rate. 
Lin et al., 
2016. 
 
24 
Patients taking an 
oral contraceptive 
(n=12 + n=42).. 
Unmasked and 
unrandomized trial. 
Two separate experiments: 1) 2 
months with 30 mg of RES in 
addition to oral contraceptive (3 
mg drospiredone and 30 m g 
ethinylestardiol) previously 
taken for 6 months; 2) Sixteen 
patients on oral contraceptives 
alone and 26 with addition of 
RES for at least 2 months prior 
to hospital admission. 
2 months 
Experiment 1: Effect 
on endometriosis related 
pain  
Experiment 2: Effect on 
aromatase and 
cyclooxygenase-2 
expression in 
endometrial tissue. 
RES significantly reduced 
pain scores (82% of 
patients reporting 
complete resolution of 
dysmenorrhea and pelvic 
pain after 2 
months of use). Inhibition 
of both aromatase and 
cyclo-oxygenase-2 
expression was 
significantly greater in the 
eutopic endometrium of 
patients taking RES 
compared with oral 
contraceptives alone. 
Maia et al., 
2012. 
25 
50 patients with 
active mild to 
moderate ulcerative 
colitis (UC). 
Randomized, double-
blind, placebo-
controlled trial. 
Patients received 500-mg RES 
or placebo. 6 weeks 
To evaluate the RES 
properties as an anti 
inflammatory and 
antioxidant agent. Effect 
on quality of life. 
RES significantly 
reduced plasma levels of 
TNF-alfa, and activity of 
NF-kB, in PBMCs. 
Samsamikor 
et al., 2016 
 
26 
Eight overweight or 
obese individuals 
(28-55 yrs old) with 
Randomized, double-
blind, placebo-
controlled trial. 
One g RES daily during 1st 
week, then 2 g daily during 2nd 
week. 
2 weeks 
To evaluate turnover of 
intestinal and hepatic 
lipoprotein (ApoB-48 
RES decreased 
production of ApoB-48 
and ApoB-100 by 22 and 
Dash et al., 
2013 
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a history of 
hypertriglyceridemia.  
and ApoB-100), whose 
high levels are markers 
of aterosclerosis, hearth 
disease and other CVD. 
27%, respectively. No 
difference in insulin 
sensitivity, fasting 
triglycerides, plasma 
cholesterol, or HDL. 
27 
Healthy overweight/ 
obese men or post-
menopausal women 
with mildly elevated 
blood pressure 
(n=19). 
Randomized, 
crossover, double 
blind, single dose, 
placebo-controlled 
trial. 
Single ingestion of 30, 
90, 270 mg of synthetic RES or 
placebo at weekly intervals. 
Analyses were performed 1 h 
after consumption of the 
product (capsules). 
Three 
acute 
doses 
Acute, dose dependent 
effect of RES on Flow 
Mediated Dilatation 
(FMD), marker of 
endotelial function 
FMD improved by 65%  
1h after consuming 
30 or 90 mg RES and by 
88% with 270 mg RES. 
 
Wong et al., 
2011 
28 Healthy adult smokers (n=50). 
Randomized, double-
blind, placebo-
controlled, cross-over 
trial. 
Follow up: patients were 
allocated to either "resveratrol-
first" group (30 days of 500 mg 
RES/day, 30 days wash-out, 30-
days placebo) or to "placebo-
first" group (30 days placebo, 
30 days wash-out, 30 days 500 
mg RES/day). 
90 days 
Effects on markers of 
inflammation and 
oxidative stress in 
smokers. 
Significant CRP and 
triglyceride 
concentrations reduction, 
and increased Total 
Antioxidant Status values. 
No significant change in 
serum uric acid, glucose, 
insulin, cholesterol, liver 
enzyme concentrations, 
and body weight, waist 
circumference, and blood 
pressure. 
 
 
 
Bo et al., 2012 
29 
27 aged physically  
inactive and non-
smokers males (60-
72 yrs old). 
Randomized, double-
blind, placebo-
controlled trial. 
Subjects were allocated to either 
a combination of exercise 
training and placebo or exercise 
training and 250 mg day of 
trans-RES 
8 weeks 
To evaluate if RES 
further enhances 
training-induced 
improvements in 
cardiovascular health 
parameters in aged men. 
The major findings were 
that 8 weeks of exercise 
training induced a number 
of beneficial 
cardiovascular effects, but 
parallel supplementation 
with resveratrol reduced 
several of these 
improvements.  
Gliemann et 
al., 2013 
30 11 obese “healthy“ men (40-65 yrs old) . 
Randomized, double-
blind, cross-over trial. 
150 mg daily of placebo or RES 
for 30 consecutive days. 
4-week washout period and then 
cross-over treatment. 
90 days 
To investigate a 30-day 
intake of RES on 
adipose tissue 
morphology. 
RES significantly reduced 
adipocyte size, which 
may contribute to the 
improvement in insulin 
sensitivity. 
Konings et al., 
2014 
31 10 obese “healthy” men with a mean age 
Randomized, double-
blind, cross-over trial. 
A 4 week washout period was 
followed by 30 days of RES 2 months 
To investigate 
postprandial incretin 
RES had no effect on 
postprandial incretin 
Knop et al., 
2013 
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of 52±2.  administration (150 mg daily) 
without other polyphenol 
consumed. 
hormone levels and 
glucagon responses. 
hormone responses, but 
showed a significant 
effect in suppressing 
postprandial glucagon 
response. 
32 
32 overweight 
“healthy” adults (60-
80 yrs old; 16 
women). Under no 
medication. 
Randomized, double-
blind, placebo-
controlled trial. 
Daily intake of placebo or 300 
or 1000 mg RES, taken in two 
doses, immediately following 
breakfast and dinner. 
12 weeks 
To determine safety and 
metabolic outcomes of 
RES supplementation in 
older adults. 
RSV was generally well 
tolerated. RSV decreased 
fasting glucose and 
bilirubin levels. 
Anton et al., 
2014 
33 
Nonobese, post-
menopausal women 
(n=45). 
Randomized, double-
blind, placebo-
controlled trial.  
75 mg/day of RES  12 weeks 
Evaluate the metabolic 
effects in nonobese, 
post-menopausal 
women with normal 
glucose tolerance. 
No change in body 
composition, resting 
metabolic rate, plasma 
lipids, or inflammatory 
markers. No increase in 
liver, skeletal muscle, or 
adipose tissue insulin 
sensitivity. No effect in 
RES putative molecular 
targets, including AMPK, 
SIRT1, NAMPT, and 
PPARGC1A, in either 
skeletal muscle or adipose 
tissue. 
 
 
 
 
 
 
Yoshino et al., 
2012 
34 Obese “healthy” men (n=24). 
Randomized, placebo-
controlled, double-
blinded, and 2-arms.  
Daily intake of three times/day 
of RES (500 mg) or placebo. 4 weeks 
Metabolic effects of 
RES in obese  subjects. 
No significant change in 
insulin sensitivity in both 
groups. Endogenous 
glucose production and 
the turnover and 
oxidation rates of glucose 
remained unchanged. No 
effect on blood pressure, 
resting energy 
expenditure, oxidation 
rates of lipid, ectopic or 
visceral fat content, or in 
inflammatory and 
metabolic biomarkers. 
Poulsen et al., 
2013. 
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35 
40 healthy post-
menopausal women 
(50-66 yrs old), with 
an average BMI of 
32.9 kg/m2.  
Open trial 
Two tablets containing 500 mg 
RES daily. Restriction in foods 
containing polyphenols was 
required two weeks before and 
during the trial.  
12 weeks 
To evaluate if RES has a 
role in systemic sex 
hormone levels and 
estrogen metabolites in 
post-menopausal women 
to reduce risk factors for 
breast cancer. 
RES intervention did not 
result in significant 
changes in sex hormone 
levels, but did result in a 
significant increase in 
sex-hormone binding 
globulin. 
 
 
Chow et al., 
2014 
36 Healthy subjects (n=40). 
Open trial, blinded for 
analysis. 
Daily ingestion of 0.5 g (n=10), 
1 g (n=10), 2.5 g (n=10) and 5 g 
(n=10) micronized RES in 
capsules. 
29 days 
Evaluation of safety, 
pharmacokinetics and 
effects on circulating 
IGF-1 and IGFBP-3, 
which are involved in 
chemioprevention 
IGF-1 levels were 
decreased on the 2.5 g 
dose and IGFBP-3 on the 
1 and 2.5 g doses. No 
linear dose-response was 
observed between RES 
plasma AUC values and 
effects on IGF-1 and 
IGFBP-3. 
 
 
 
 
Brown et al., 
2010 
37 
Women at higher 
breast cancer risk 
(n=31). 
Randomized, 3-arm, 
double-blind, placebo-
controlled trial. 
Daily ingestion of placebo, 5 
mg  or 50 mg RES in capsules. 3 months 
Effects on DNA 
methylation and 
prostaglandin E2. 
No significant effect on 
the 4 genes studies 
(RASSF-1a, APC, 
CCND2 and p16). A 
correlation was found 
between the decrease of 
RASSSF-1a 
methylation and serum 
RES concentration. 
Zhu et al., 
2012 
38 
16 healthy male, 
mean age of 22 
years, performing 3 
days /week of high 
intensity training. 
Unspecified 
medication, if any. 
Randomized, double-
blind, placebo-
controlled trial. 
Daily intake of placebo or 150 
mg RES. Subjects were 
informed to refrain from 
consuming foods and drinks 
containing polyphenols for the 
duration of the study. No 
nutritional supplement allowed. 
4 weeks 
To investigate the 
effects of RES in high-
intensity training. 
RES did not affect 
aerobic or anaerobic 
capacity, or exercise 
substrate utilization, 
during training. 
Scribbans et 
al., 2014 
39 
42 healthy but 
physically inactive 
man (60–72 yrs old). 
Randomized, double-
blind, placebo 
controlled trial. 
Subjects from the first part were 
assigned to either a combination 
of exercise training with 
placebo or exercise training 
with 250 mg RES/day 
8 weeks 
To investigate the 
effects of RES alone and 
combined with exercise 
training on metabolic 
and inflammatory status 
in skeletal muscle. 
Exercise training 
markedly increased 
muscle endurance and the 
content and activity of 
oxidative proteins as well 
as decreased the TNFα  
mRNA content and 
Olensen et al., 
2014 
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protein carbonylation 
level in skeletal muscle, 
which are involved in 
inflammation and 
oxidative stress. RES  did 
not affect these 
parameters. 
40 
13 healthy, sedentary 
adults (18-65 yrs 
old).  
Randomized, double-
blind, placebo 
controlled, cross-over 
trial. 
RES and placebo were 
admistered twice daily. 
Regarding RES, the dose in the 
first week, was 500 mg (x2). 
This was increased to 1000 mg 
(x2) for the remaining 3 weeks 
if tolerated by the patient. Then 
cross-over 
4 weeks 
To assess the effect of 
RES on exercise 
capacity . 
RES did not show any 
significant effect on 
exercise capacity or any 
other exercise parameters.  
Voduc et al., 
2014 
41 Obese men (n=11). 
Randomized, 
crossover, double-
blind, placebo-
controlled trial. 
Daily ingestion of 150 mg of 
synthetic RES in capsules. 1 month 
To assess whether RES 
induces metabolic 
changes in obese 
men. 
RES induced modest but 
consistent metabolic 
changes that mimic 
caloric restriction, such as 
reduction of sleeping 
and resting metabolic 
rate, activation of AMPK 
and increase of SIRT1 
and PGC-1 in muscle, and 
others. 
Timmers et 
al., 2011 
42 Healthy subjects (n=22). 
Randomized, 
crossover, double-
blind, dose-response, 
placebo-controlled 
trial. 
Single intake of placebo, 250 
mg or 500 mg RES in capsules. 
Analyses were performed 45 
min after the ingestion.  
Acute 
dose 
Acute effect on brain 
functions by improving 
blood flow. 
RES increased dose-
dependently cerebral 
blood flow. Cognitive 
function was not 
affected. 
Kennedy et 
al., 2010 
43 Healthy subjects (n=42). Open Trial. 
Cohort with a single arm to 
evaluate effects upon daily 
ingestion of 1 g RES in 
capsules. 
4 weeks Effect of RES on CYPs and phase II enzymes. 
RES inhibited the activity 
of CYP3A4, CYP2D6, 
and CYP2C9 and induced 
CYP1A2, with possible 
effect on drug 
metabolism. 
Chow et al., 
2010 
44 74 middle aged obese men (41.8-
Randomized, double-
blind, placebo-
Placebo or intake of 500 
mg/day, or 75 mg twice daily. 
16 
weeks. 
To evaluate the effects 
of RES on bone 
Bone density increased in 
a dose-dependent manner 
Ornstrup et 
al., 2014 
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56.8 yrs old), with 
metabolic syndrome.  
controlled trial. Participants were instructed to 
avoid nutritional supplements 
during the study 
turnover markers, bone 
mass and structure. 
by stimulating bone 
mineralization. 
45 
10 healthy male 
volunteers (21–28 
yrs old).  
Randomized open 
trial. 
One single 5 g dose of RES. 
Subjects received a standard 
diet not containing polyphenols 
during the study period. 
48 hours 
To determine the effect 
of RES on human 
mononuclear cells upon 
bacterial stimulation. 
RES-treated individuals 
showed an increase in 
TNF-a levels after a 24-h 
treatment while IL-10 
levels decreased. In this 
study, RES shows anti-
inflammatory  and 
immunomodulant 
properties. 
Gualdoni et 
al., 2014 
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Table 3 – Summary of resveratrol’s effects in humans with different diseases 
 
Area  No. of studies (Ref. to Table 1) 
Daily dose range 
(Lowest active dose) Comments 
Cancer 3 (1-3) 0.07-5 g (0.07 g) 
Positive effects on markers of 
cellular proliferation, migration 
and apoptosis. 
Fatty liver 3 (4-6) 0.3 -3 g (0.3 g) 
Reduction of hepatic enzymes and 
opposing results on inflammatory 
markers. 
CVD 7 (7-12) 0.5-200 mg (0.5 mg) 
In most studies, reduction of LDL-
cholesterol (>8 mg) and some 
inflammatory markers (>0.5 mg). 
Metabolic 
syndrome 3 (13-15) 
0.1-1.5 g 
(1.5 g) 
No significant effects on flow 
mediated dilatation till 0.1 g/day.  
Positive modulation of metabolic 
syndrome parameters at 1.5 g/day. 
Diabetes 5 (16-20) 0.01-3 g (0.01 g) 
Most studies showed improvement 
of insuline sensitivity; 
contradictory results in reduction 
of glycemia. 
Cognitive 
functions 2 (21-22) 
0.075-2 g 
(0.075 g) 
General improvement of cognitive 
fuctions requiring further research 
to be confirmed. 
Other 3 (23-25) 0.03-0.5 g  
Reduction of pain score in women 
with dysmenorrhea (30 mg/day) 
and improvement of inflammatory 
biomarkers in ulcerative colitis 
(500 mg/day). Improvement in 
mean net ultrafitration volume and 
rate in dialized patients (>450 
mg/day). 
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Table 4 – Summary of resveratrol’s effects in healthy humans  
 
Area  
N.of studies 
(Ref. to Table 
1) 
Daily dose range 
(Lowest active dose) Comments 
Cardiovascular 4 (26-29) 
0.030-2 g 
(0.030 for endotelial 
function) 
Decreased levels of risk 
factors for CVD:  ApoB48 and 
ApoB100, endotelial function 
and oxidative stress, etc. 
Insulin sensitivity 5 (30-34) 0.075-1 g 
No significant result on 
glycemia and insulin 
sensitivity. 
Chemioprevention 3 (35-37) 0.005-5 g No significant effect. 
Training 
performance 4 (38-41) 0.15-2 g 
No effects on training 
performance. 
Cognitive function 1 (42) 0.250-0.5 (0.25) 
No effect on cognitive 
function, improvement in 
cerebral blood flow. 
Hepatic metabolic 
function 1 (43) 1 g 
Possible effect (positive or 
negative) on hepatic 
metabolism of drug. 
Bone 
mineralization 1 (44) 0.15-0.5 g 
Dose-response improvement 
of bone density. 
Immunomodulation 1 (45) 5 g 
Improvement of 
immunomodulation and 
inflammation. 
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Figure Legends 
 
Figure 1. Oxidative stress snowball effect. Stages on redox homeostasis evolution in time. In 
(y) redox homeostasis in (x) years 
 
Figure 2. Evolution of oxidative stress in time. 1) cellular breathing oxidative status average; 
2) oxidative stress by physiological stimulation (e.g. postprandial); 3) and 4) acute to mild 
chronic oxidative stress; 5) acute to moderate chronic oxidative stress; 6) acute to severe 
chronic oxidative stress (Modified from Preiser, 2012). 
 
 
